WO2008096082A3 - Procédé de mesure de la concentration de facteur vii activé (fviia) dans un échantillon - Google Patents

Procédé de mesure de la concentration de facteur vii activé (fviia) dans un échantillon Download PDF

Info

Publication number
WO2008096082A3
WO2008096082A3 PCT/FR2007/002188 FR2007002188W WO2008096082A3 WO 2008096082 A3 WO2008096082 A3 WO 2008096082A3 FR 2007002188 W FR2007002188 W FR 2007002188W WO 2008096082 A3 WO2008096082 A3 WO 2008096082A3
Authority
WO
WIPO (PCT)
Prior art keywords
sample
concentration
fviia
thrombinogram
measuring
Prior art date
Application number
PCT/FR2007/002188
Other languages
English (en)
Other versions
WO2008096082A2 (fr
Inventor
Lysiane Hilbert
Dominique Grenier
Claudine Mazurier
Original Assignee
Lfb Biotechnologies Soc Par Ac
Lysiane Hilbert
Dominique Grenier
Claudine Mazurier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lfb Biotechnologies Soc Par Ac, Lysiane Hilbert, Dominique Grenier, Claudine Mazurier filed Critical Lfb Biotechnologies Soc Par Ac
Priority to CA002673623A priority Critical patent/CA2673623A1/fr
Priority to EP07872461A priority patent/EP2100148A2/fr
Priority to US12/520,019 priority patent/US20100009396A1/en
Priority to AU2007346300A priority patent/AU2007346300A1/en
Priority to JP2009543505A priority patent/JP2010515045A/ja
Publication of WO2008096082A2 publication Critical patent/WO2008096082A2/fr
Publication of WO2008096082A3 publication Critical patent/WO2008096082A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96447—Factor VII (3.4.21.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un procédé de mesure in vitro ou ex-vivo de la concentration de FVII dans un échantillon, comprenant les étapes consistant à : a) mélanger ledit échantillon avec un plasma humain dépourvu de FVII et d'au moins un autre facteur choisi parmi le FVIII, le FIX et le FXI; b) ajouter des composants initiateurs de la réaction de génération de thrombine comprenant une source d'ions calcium, un agent phospholipidique et du facteur tissulaire; c) effectuer un test de génération de thrombine (TGT) sur le milieu réactionnel ainsi obtenu afin d'obtenir un thrombinogramme fournissant des paramètres; d) comparer au moins l'un des paramètres du thrombinogramme à un paramètre homologue de thrombinogrammes standards, chaque thrombinogramme standard étant obtenu avec une concentration étalon fixée de FVIIa dans ledit milieu réactionnel, comprise dans une plage allant de 1 pM à 5 nM, et e) déduire de l'étape d) une mesure de la concentration de FVIIa de l'échantillon comprise dans ladite plage.
PCT/FR2007/002188 2006-12-29 2007-12-28 Procédé de mesure de la concentration de facteur vii activé (fviia) dans un échantillon WO2008096082A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002673623A CA2673623A1 (fr) 2006-12-29 2007-12-28 Procede de mesure de la concentration de facteur vii active (fviia) dans un echantillon
EP07872461A EP2100148A2 (fr) 2006-12-29 2007-12-28 Procédé de mesure de la concentration de facteur vii activé (fviia) dans un échantillon
US12/520,019 US20100009396A1 (en) 2006-12-29 2007-12-28 Method for measuring the concentration of activated factor vii (fviia) in a sample
AU2007346300A AU2007346300A1 (en) 2006-12-29 2007-12-28 Method for measuring the concentration of activated factor VII (FVIIa) in a sample
JP2009543505A JP2010515045A (ja) 2006-12-29 2007-12-28 サンプル中の因子ＶＩＩａ（ＦＶＩＩａ）の濃度を測定する方法及びこの方法を実施するために用いるキット、そして因子を欠失した血漿を用いてサンプル中の因子ＶＩＩ（ＦＶＩＩａ）の濃度を測定する方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0611535A FR2910969B1 (fr) 2006-12-29 2006-12-29 Procede de mesure de la concentration de facteur viia (fviia) dans un echantillon
FR06/11535 2006-12-29

Publications (2)

Publication Number Publication Date
WO2008096082A2 WO2008096082A2 (fr) 2008-08-14
WO2008096082A3 true WO2008096082A3 (fr) 2008-11-13

Family

ID=38134121

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2007/002188 WO2008096082A2 (fr) 2006-12-29 2007-12-28 Procédé de mesure de la concentration de facteur vii activé (fviia) dans un échantillon

Country Status (10)

Country Link
US (1) US20100009396A1 (fr)
EP (1) EP2100148A2 (fr)
JP (1) JP2010515045A (fr)
KR (1) KR20090119753A (fr)
CN (1) CN101573622A (fr)
AR (1) AR064682A1 (fr)
AU (1) AU2007346300A1 (fr)
CA (1) CA2673623A1 (fr)
FR (1) FR2910969B1 (fr)
WO (1) WO2008096082A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2933496B1 (fr) * 2008-07-02 2012-10-05 Lfb Biotechnologies Procede de mesure du taux de facteur vii active dans un echantillon
FR2967781B1 (fr) 2010-11-18 2019-06-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Determination du pouvoir thrombogene d'immunoglobulines humaines
WO2014098056A1 (fr) * 2012-12-18 2014-06-26 第一三共株式会社 Procédé de mesure de la production de thrombine
WO2015091115A1 (fr) * 2013-12-19 2015-06-25 Koninklijke Philips N.V. Procédé de détermination du risque hémostatique d'un sujet

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003004694A1 (fr) * 2001-07-03 2003-01-16 Oklahoma Medical Research Foundation Analyse destinee a mesurer les complexes facteur viia-antithrombine
US20030211460A1 (en) * 2000-06-30 2003-11-13 Nelsestuen Gary L. Methods for detecting activity of clottings factors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3947378A (en) * 1974-12-23 1976-03-30 Warner-Lambert Company Adsorbed plasma
DE122007000007I2 (de) * 1986-04-09 2010-12-30 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US5472850A (en) * 1991-04-10 1995-12-05 Oklahoma Medical Research Foundation Quantitative clotting assay for activated factor VII
DE19634312A1 (de) * 1996-08-24 1998-02-26 Behringwerke Ag Verfahren zur Herstellung von Faktor V-Mangelplasma und ein so erhaltenes Mangelplasma
RU2373282C2 (ru) * 2003-06-19 2009-11-20 Байер Хелткэр Ллк ВАРИАНТЫ ДОМЕНА GLA ФАКТОРА VII ИЛИ VIIa
JP4377207B2 (ja) * 2003-11-28 2009-12-02 シスメックス株式会社 血液凝固時間測定方法および血液凝固時間測定用試薬

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030211460A1 (en) * 2000-06-30 2003-11-13 Nelsestuen Gary L. Methods for detecting activity of clottings factors
WO2003004694A1 (fr) * 2001-07-03 2003-01-16 Oklahoma Medical Research Foundation Analyse destinee a mesurer les complexes facteur viia-antithrombine

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AUDU P. ET AL.: "The impact of tissue factor pathway inhibitor on coagulation kinetics determined by thromboelastography.", ANESTH. ANALG., vol. 103, no. 4, October 2006 (2006-10-01), pages 841 - 845, XP009085375 *
BLOOD, vol. 106, no. 11, Part 1, November 2005 (2005-11-01), 47TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; ATLANTA, GA, USA; DECEMBER 10 -13, 2005, pages 605A, ISSN: 0006-4971 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 2005 (2005-11-01), CHITLUR M.B. ET AL.: "Thromboelastography in children with coagulation factor deficiencies.", XP009085367, Database accession no. PREV200600184509 *
NIELSEN V.G. ET AL.: "Effects of coagulation factor deficiency on plasma coagulation kinetics determined via thrombelastography(R): critical roles of fibrinogen and factors II, VII, X and XII.", ACTA ANAESTHESIOL. SCAND., vol. 49, no. 2, February 2005 (2005-02-01), pages 222 - 231, XP002383695, ISSN: 0001-5172 *

Also Published As

Publication number Publication date
JP2010515045A (ja) 2010-05-06
AU2007346300A1 (en) 2008-08-14
FR2910969B1 (fr) 2009-02-27
KR20090119753A (ko) 2009-11-19
EP2100148A2 (fr) 2009-09-16
US20100009396A1 (en) 2010-01-14
WO2008096082A2 (fr) 2008-08-14
AR064682A1 (es) 2009-04-22
CA2673623A1 (fr) 2008-08-14
CN101573622A (zh) 2009-11-04
FR2910969A1 (fr) 2008-07-04

Similar Documents

Publication Publication Date Title
Muramoto et al. ToF-SIMS analysis of adsorbed proteins: principal component analysis of the primary ion species effect on the protein fragmentation patterns
WO2008096082A3 (fr) Procédé de mesure de la concentration de facteur vii activé (fviia) dans un échantillon
WO2003106964A3 (fr) Procedes et dispositifs a haut rendement permettant de doser des analytes dans un echantillon fluidique
WO2003004677A3 (fr) Procedes de creation de profils differentiels par la combinaison de donnees obtenues par des mesures separees
DK1520039T3 (da) Mitokondrisk polymorfi, forbundet til en prædisposition til udvikling af uhensigtsmæssig ardannelse og fibrose
WO2007120699A3 (fr) Réactifs et méthodes d'utilisation de cellules souches embryonnaires humaines pour évaluer la toxicité de composés pharmaceutiques et d'autres substances chimiques
WO2005030030A3 (fr) Procede et dispositif pour fluorimetrie par mesure de rapport
GB2426592B (en) Method for the concentration measurement of gases
WO2006007403A3 (fr) Methodes d'identification et de mesure de liaisons s-nitrosothiol dans des cellules et des molecules contenant des hemes
WO2012120546A3 (fr) Procédé de surveillance d'une anticoagulothérapie
DK1513878T3 (da) Sammensætninger og fremgangsmåder til analyse af Apo B48 og Apo B100
Maase et al. Combined Raman-and AFM-based detection of biochemical and nanomechanical features of endothelial dysfunction in aorta isolated from ApoE/LDLR−/− mice
CY1110543T1 (el) Προϊον και μεθοδος
WO2006061646A8 (fr) Dosage pour produire un profil lipidique au moyen d'une mesure de fluorescence
EP2752495B1 (fr) Procédé de détermination de l'activité d'une enzyme protéolytique (variantes), dispositif pour la mise en oeuvre de celui-ci et procédé de diagnostic
WO2005040759A3 (fr) Dispositif et methodes destines a la detection d'une substance a analyser cible
DE602006021131D1 (de) Verfahren zur Bestimmung des Phänotyps von Zellen
WO2007022086A3 (fr) Anticorps et methodes permettant de prevoir la formation de caries dentaires
US20110097754A1 (en) Method for measuring activated factor vii level in a sample
EP2044212A4 (fr) Procedes d'identification de patients courant un risque accru d'episode cardiovasculaire indesirable
CA2586654A1 (fr) Utilisation de la proteine asc comme marqueur du cancer colorectal
ATE481639T1 (de) Lumineszenztest mit verwendung makrocyclischer lanthanid(iii)-komplexe
WO2009132100A3 (fr) Méthode de création d’un étalon pour plusieurs analytes présents dans une matière première d’origine biologique
Theobaldo et al. Effect of heavy metals contamination from cigarette smoke on sound and caries-like enamel
Bollet‐Quivogne et al. Scanning microradiographic study on the influence of diffusion in the external liquid on the rate of demineralization in hydroxyapatite aggregates

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780048632.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07872461

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 3926/DELNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 12520019

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2673623

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020097013197

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2009543505

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007872461

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007346300

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2007346300

Country of ref document: AU

Date of ref document: 20071228

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: PI0721242

Country of ref document: BR

Free format text: APRESENTE DOCUMENTOS COMPROBATORIOS QUE EXPLIQUEM A DIVERGENCIA NO NOME DO DEPOSITANTE CONSTANTE NA PUBLICACAO INTERNACIONAL WO2008/096082 DE 14/08/2008 "LFB BIOTECHNOLOGIES SOCIETE PAR ACTIONS SIMPLIFIEE UNIPERSONNELLE" E O CONSTANTE DA PETICAO INICIAL NO 016090004047 DE 25/06/2009, "LFB BIOTECHNOLOGIES", REGULARIZANDO INCLUSIVE A PROCURACAO.

ENPW Started to enter national phase and was withdrawn or failed for other reasons

Ref document number: PI0721242

Country of ref document: BR

Free format text: PEDIDO RETIRADO EM RELACAO AO BRASIL POR NAO ATENDER AS DETERMINACOES REFERENTES A ENTRADA DO PEDIDO NA FASE NACIONAL E POR NAO CUMPRIMENTO DA EXIGENCIA FORMULADA NA RPI NO 2257 DE 08/04/2014